CD274 and neoplasm: Although tumour or immune cells directed precise genomics diagnosis,29 including tumour mutation burden,30, 31 and PD‐1/PD‐L1 examinations,32, 33 have been extensively accepted as the preliminary explanations for responsive evaluations to ICIs, the presence of primary or acquired resistance to them still conflicts with the practical effectiveness of anti‐tumour immune therapies.34